Predictive value of plasma sICAM-1 and sP-Selectins in the risk of death in patients with acute respiratory distress syndrome
Abstract
Objective: To evaluate the predictive value of sICAM-1 and sP-Selectins in the risk of death in a prospective cohort of adult acute respiratory distress syndrome (ARDS).
Methods: Adult ARDS patients were included. Plasma sICAM-1, sP-Selectins, and inflammatory cytokines (TNF-α, IL-1β, IL-6, IL-8, and IL-17A) were detected in ARDS subjects. The correlation between different factors and the potential of sICAM-1 and sP-Selectins as endothelial markers to predict the risk of death from ARDS was analyzed.
Results: Plasma sICAM-1 and sP-Selectins were higher in ARDS patients and higher in non-survivors of ARDS. sICAM-1 was significantly correlated with TNF-α, IL-6 and IL-8, and sP-Selectins was also significantly correlated with IL-6 and IL-8. Above the critical values of 245.5 ng/mL (sICAM-1) and 482.5 ng/mL (sP-Selectins), the death of the ARDS population increased. High plasma sICAM-1 and sP-Selectins at ICU admission were independent predictors of death of ARDS patients.
Conclusion: sICAM-1 and sP-Selectins can predict the risk of death in critically ill patients with ARDS.
Copyright (c) 2023 Jing Pan, ChaoMin Wu, ChunLing Du, Lei Zhou, Liang Gu
This work is licensed under a Creative Commons Attribution 4.0 International License.
The published articles will be distributed under the Creative Commons Attribution 4.0 International License (CC BY). It is allowed to copy and redistribute the material in any medium or format, and remix, transform, and build upon it for any purpose, even commercially, as long as appropriate credit is given to the original author(s), a link to the license is provided and it is indicated if changes were made. Users are required to provide full bibliographic description of the original publication (authors, article title, journal title, volume, issue, pages), as well as its DOI code. In electronic publishing, users are also required to link the content with both the original article published in Journal of Medical Biochemistry and the licence used.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.